Compare Davita Inc (DVA) vs Ionis Pharmaceuticals Inc. Common Stock (IONS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Davita Inc trades at $183.33 (market cap $11.53B), while Ionis Pharmaceuticals Inc. Common Stock trades at $43.96 (market cap $7.10B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.
| DVA | IONS | |
|---|---|---|
Market Cap | $11.53B | $7.10B |
Volume | 444,368 | 2,027,457 |
Sector | Health | Health |
52-Week High | $240.96 | $86.50 |
52-Week Low | $103.87 | $42.38 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.25B | $6.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $182.08, up 0.17% with a bullish technical signal and strong institutional backing. The stock shows consistent earnings beats with Q2 2026 EPS of $4.02 exceeding expectations. Revenue growth has been steady from $11.6B in 2022 to $13.64B in 2025, though net margins fluctuated. Recent partnership expansion with Humana for value-based kidney care demonstrates strategic growth initiatives. The stock trades at reasonable valuations with P/E of 15.31 and P/S of 0.9, while maintaining strong profitability metrics including 635.3% ROE.
DVA presents a compelling investment case with analyst consensus price target of $235.67 offering 29% upside potential. The company benefits from demographic tailwinds in healthcare services and Warren Buffett's significant ownership. However, investors face risks from regulatory pressures, debt levels at 65.55% of assets, and margin compression concerns highlighted in recent earnings. The stock's technical position near key support at $181 requires monitoring for sustained bullish momentum.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →
